MedTrace Logo

Clinical Trial Using Bone Marrow-derived Mononuclear Cells for Spinal Cord Injury

NCT02923817 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2017-01-10

No results posted yet for this study

Summary

The purpose of study is to determine whether autologous mononuclear cells deriving from the bone marrow are effective in the treatment of spinal cord injury.

Conditions

  • Spinal Cord Injuries

Interventions

BIOLOGICAL

Transplantation of autologous bone marrow-derived mononuclear cells by lumbar injection

Sponsors & Collaborators

  • Kitano Hospital

    collaborator UNKNOWN

  • Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan

    collaborator OTHER

  • Da Nang Hospital

    lead OTHER

Principal Investigators

  • Ba Ngoc Nguyen, MD · Danang Hospital

  • Yoshihisa Suzuki, MD, PhD. · Kitano Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2018-12-31
Completion
2019-06-30

Countries

  • Vietnam

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02923817 on ClinicalTrials.gov